应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
EMA Emera Inc.
已收盘 08-14 16:00:00 EDT
47.56
+0.45
+0.96%
盘后
47.56
+0.00
0.00%
17:52 EDT
最高
47.66
最低
46.88
成交量
25.18万
今开
46.99
昨收
47.11
日振幅
1.66%
总市值
142.35亿
流通市值
142.22亿
总股本
2.99亿
成交额
1,195万
换手率
0.08%
流通股本
2.99亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
以诺康启动上市辅导;绿谷971再注册申请未获批准
21世纪经济报道 · 08-14 00:34
以诺康启动上市辅导;绿谷971再注册申请未获批准
港股异动 | 复宏汉霖(02696)再涨超5% H药汉斯状进入印度市场 HLX14此前获EMA积极审评意见
智通财经 · 08-05
港股异动 | 复宏汉霖(02696)再涨超5% H药汉斯状进入印度市场 HLX14此前获EMA积极审评意见
百济神州BGB-16673获EMA优先药物认定
DoNews · 07-31
百济神州BGB-16673获EMA优先药物认定
复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见
智通财经 · 07-28
复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见
百奥泰BAT2506注射液上市许可申请获FDA受理
财中社 · 07-16
百奥泰BAT2506注射液上市许可申请获FDA受理
7月15日技术分析报告:现货黄金、WTI原油期货
金十数据 · 07-16
7月15日技术分析报告:现货黄金、WTI原油期货
诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理
智通财经 · 07-09
诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理
突破通用领域推理的瓶颈!清华NLP实验室强化学习新研究RLPR
市场资讯 · 06-27
突破通用领域推理的瓶颈!清华NLP实验室强化学习新研究RLPR
乐普生物:EGFR ADC联合PD-1单抗IND申请获EMA批准
生物药大时代 · 06-26
乐普生物:EGFR ADC联合PD-1单抗IND申请获EMA批准
港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知
智通财经 · 06-24
港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知
一年两针!吉利德突破性长效HIV疗法获FDA批准上市
药渡 · 06-19
一年两针!吉利德突破性长效HIV疗法获FDA批准上市
海普瑞(002399.SZ):依诺肝素钠注射液获得EMA新增生产商批准
智通财经 · 06-17
海普瑞(002399.SZ):依诺肝素钠注射液获得EMA新增生产商批准
加载更多
公司概况
公司名称:
Emera Inc.
所属市场:
NYSE
上市日期:
--
主营业务:
Emera Incorporated是一家北美能源服务提供商,成立于1998年7月23日,拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州,另外还在加拿大大西洋省、新墨西哥州和加勒比地区开展业务。Emera总部位于新斯科舍省哈利法克斯。
发行价格:
--
{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":47.56,"timestamp":1755201600000,"preClose":47.11,"halted":0,"volume":251836,"hourTrading":{"tag":"盘后","latestPrice":47.56,"preClose":47.56,"latestTime":"17:52 EDT","volume":202120,"amount":9629235.696265,"timestamp":1755208325527},"delay":0,"floatShares":299032665,"shares":299300000,"eps":2.177014,"marketStatus":"已收盘","change":0.45,"latestTime":"08-14 16:00:00 EDT","open":46.99,"high":47.655,"low":46.875,"amount":11954530.26118,"amplitude":0.016557,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.177014,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1755244800000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":47.11,"dividendRate":0.044178,"postHourTrading":{"tag":"盘后","latestPrice":47.56,"preClose":47.56,"latestTime":"17:52 EDT","volume":202120,"amount":9629235.696265,"timestamp":1755208325527},"volumeRatio":1.669396,"impliedVol":0.1012,"impliedVolPercentile":0.1111},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"2559936877","title":"以诺康启动上市辅导;绿谷971再注册申请未获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2559936877","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559936877?lang=zh_cn&edition=full","pubTime":"2025-08-14 08:34","pubTimestamp":1755131649,"startTime":"0","endTime":"0","summary":"根据新闻稿,Brinsupri是首个获FDA批准用于NCFB的治疗方案。资本市场高端医疗器械企业以诺康启动上市辅导8月12日,证监会网站披露,以诺康医疗科技(苏州)股份有限公司在江苏证监局上市辅导备案,辅导机构为华泰证券。截止本公告日,博灵脑机产品尚未正式上市,仅因与科研机构合作而销售少量产品。舆情预警绿谷971再注册申请未获批准2025年8月12日,国家药监局政务服务门户网站发布通知,绿谷制药的甘露特钠胶囊再注册申请未获批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814083654a6e4c64a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250814083654a6e4c64a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1223082196.USD","LU1223082519.USD","LU1223083913.SGD","BK4017","EMA","CDE","BK4081","AD"],"gpt_icon":0},{"id":"2557794359","title":"港股异动 | 复宏汉霖(02696)再涨超5% H药汉斯状进入印度市场 HLX14此前获EMA积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2557794359","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557794359?lang=zh_cn&edition=full","pubTime":"2025-08-05 11:22","pubTimestamp":1754364167,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,复宏汉霖再涨超5%,截至发稿,涨5.28%,报70.8港元,成交额1515.65万港元。消息面上,7月31日,复宏汉霖宣布,其自主研发的抗PD-1单抗H药已完成首批面向印度市场的发货。至此,汉斯状已在近40个国家和地区获批。此外,复宏汉霖近日公布,公司自主研发的Prolia与Xgeva生物类似药HLX14获得欧洲药品管理局人用药品委员会的积极审评意见,推荐批准其上市许可申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1325721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MNDmain","02696","BK4081","EMA","BK1161"],"gpt_icon":0},{"id":"2555846748","title":"百济神州BGB-16673获EMA优先药物认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2555846748","media":"DoNews","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555846748?lang=zh_cn&edition=full","pubTime":"2025-07-31 18:45","pubTimestamp":1753958703,"startTime":"0","endTime":"0","summary":"2025年7月31日,百济神州宣布,欧洲药品管理局(EMA)已授予其在研布鲁顿氏酪氨酸激酶(BTK)降解剂BGB-16673优先药物(PRIME)认定,用于治疗既往接受过BTK抑制剂治疗的华氏巨球蛋白血症(WM)患者。EMA人用药品委员会(CHMP)还就该药物的欧盟孤儿药资格认定申请发布了积极意见,最终决定预计几周后公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118482794c605e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118482794c605e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4585","BK4081","BK4526","BK4139","ONC","BGB"],"gpt_icon":0},{"id":"2554877836","title":"复宏汉霖(02696):地舒单抗生物类似药HLX14(重组抗RANKL全人单克隆抗体注射液)获欧洲药品管理局(EMA)人用医药产品委员会(CHMP)积极审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877836","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877836?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:17","pubTimestamp":1753697873,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复宏汉霖(02696)发布公告,近日,HLX14获EMA人用医药产品委员会(Committee for Medicinal Products for Human Use,“CHMP”)积极审评意见,推荐批准HLX14的上市许可申请。CHMP的审评意见将会被递交至欧盟委员会(European Commission,“EC”),EC将参考该意见并在未来2-3个月做出最终审查决定。一旦获得EC批准,HLX14的集中上市许可将在所有欧盟成员国及欧洲经济区(EEA)国家冰岛、列支敦士登和挪威生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHMP","EMA","02696","BK4081","09939","BK4087","BK1161","BK1574","159938","BK1515"],"gpt_icon":0},{"id":"2551145456","title":"百奥泰BAT2506注射液上市许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2551145456","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551145456?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:53","pubTimestamp":1752652394,"startTime":"0","endTime":"0","summary":"7月16日,百奥泰发布公告,近日收到BAT2506注射液生物制品许可申请获得美国FDA受理的通知。公告中提到,BAT2506的原研药为美国强生公司的Simponi,根据强生公司2024年年度报告,Simponi2024年在全球的销售额为21.9亿美元。公司已在全球多个区域开展BAT2506的商业化进程,并获得中国NMPA、美国FDA、欧洲EMA、巴西ANVISA的上市许可申请受理。2025年一季度,百奥泰实现收入2.07亿元,归母净利润-9333万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161556269544908d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161556269544908d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2552127649","title":"7月15日技术分析报告:现货黄金、WTI原油期货","url":"https://stock-news.laohu8.com/highlight/detail?id=2552127649","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552127649?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:47","pubTimestamp":1752644820,"startTime":"0","endTime":"0","summary":"本文汇总Economies.com的分析师今日最新观点,包括现货黄金、WTI原油期货等多个品种!现货黄金价格获得更多支撑Economies.com的分析师今日最新观点:现货黄金在上个交易日上涨,得益于其倚靠EMA50均线支撑,这有助于减缓之前的看跌浪潮并为价格企稳提供机会。WTI原油期货试图收复部分前期跌幅Economies.com的分析师今日最新观点:WTI原油期货在上个交易日小幅上涨,试图收复部分前期跌幅。尽管出现上涨,但油价仍面临明显技术压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717013617a6adf1c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717013617a6adf1c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4570","BK4081","SCO","UCO","USO","BK4585","BK4588","EMA"],"gpt_icon":0},{"id":"2550681411","title":"诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550681411?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月8日,诺和诺德(NVO.US)宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理,用于体重管理。此次上市申请是基于III期STEP UP研究和III期STEP UP T2D研究的积极结果。结果显示,患者平均基线体重为113kg,治疗第72周,7.2mg司美格鲁肽组、2.4mg司美格鲁肽组和安慰剂组患者的体重分别减轻了20.7%、17.5%和2.4%。此外,7.2mg司美格鲁肽组有33.2%的患者实现了体重减轻25%以上的效果,而2.4mg司美格鲁肽组和安慰剂组的这一比例分别为16.7%和0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","LU1093756325.SGD","BK4599","LU0154236417.USD","BK4081","BK4532","IE00BZ1G4Q59.USD","BK4007","BK4588","NVO","LU1093756168.USD","BK4585","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2546642507","title":"突破通用领域推理的瓶颈!清华NLP实验室强化学习新研究RLPR","url":"https://stock-news.laohu8.com/highlight/detail?id=2546642507","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546642507?lang=zh_cn&edition=full","pubTime":"2025-06-27 10:30","pubTimestamp":1750991400,"startTime":"0","endTime":"0","summary":"针对这一关键挑战,清华大学自然语言处理实验室提出了一项关键性技术 —— 基于参考概率奖励的强化学习。同时,RLPR 提出基于奖励标准差的动态过滤机制,进一步提升强化学习的稳定性和性能提升。目前 RLPR 相关代码、模型、数据、论文均已开源。结果表明,PR 在 0.5B 规模即取得了显著优于规则奖励和验证器模型奖励的质量。RLPR 在 Gemma、Llama、Qwen 等不同基座模型上均稳定提升推理能力总结RLPR 提出了创新的 Prob-to-Reward 奖励机制,解决了现有 RLVR 范式的领域依赖问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-27/doc-infcnrzr2751855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0006061336.USD","BK4081","BK4585","EMA","RL","BK4588","BK4202"],"gpt_icon":0},{"id":"2546275727","title":"乐普生物:EGFR ADC联合PD-1单抗IND申请获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546275727","media":"生物药大时代","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546275727?lang=zh_cn&edition=full","pubTime":"2025-06-26 09:45","pubTimestamp":1750902347,"startTime":"0","endTime":"0","summary":"2025年6月24日,乐普生物科技股份有限公司的MRG003联合普特利单抗对比MRG003单药治疗局部晚期头颈鳞癌的II期研究的临床试验申请获得欧洲药品管理局批准,计划将于2025Q3启动入组。该研究是全球首个EGFR ADC联合PD-1单抗在局晚期头颈鳞癌的临床研究。EGFR ADC与普特利单抗联合治疗在EGFR阳性实体瘤患者中具有良好的耐受性和令人鼓舞的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","EMA","BK1161"],"gpt_icon":0},{"id":"2545847686","title":"港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545847686?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,海普瑞午前涨超3%,截至发稿,涨3.09%,报5.33港元,成交额872.01万港元。消息面上,海普瑞发布公告,公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍,海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动,首期新建三条预灌封生产线设计产能为3.3亿支╱年,其按照中国、欧美药品法规标准设计建造,用于生产依诺肝素钠预灌封注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","EMA","BK4081","BK1191","09989","002399","BK0239","BK0188"],"gpt_icon":0},{"id":"2544194287","title":"一年两针!吉利德突破性长效HIV疗法获FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544194287","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544194287?lang=zh_cn&edition=full","pubTime":"2025-06-20 07:31","pubTimestamp":1750375894,"startTime":"0","endTime":"0","summary":"4吉利德深耕HIV领域吉利德科学公司在HIV治疗和预防领域拥有超过35年的创新经验。吉利德致力于通过科学创新提供满足HIV患者不断变化需求的解决方案。通过与全球健康倡导者和组织的合作,吉利德还旨在改善教育、扩大药物可及性,并解决护理障碍,目标是终结全球HIV流行。这种每年仅需注射两次的长效方案有望显著提高患者的依从性,降低HIV传播风险,推动全球HIV预防目标的实现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823416689.USD","LU0109394709.USD","BK4550","LU0320765992.SGD","LU1674673691.USD","LU0058720904.USD","BK4532","LU0889565916.HKD","BK4566","LU2087621335.USD","LU1778281490.HKD","LU2089984988.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU1571399168.USD","GILD","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU1839511570.USD","EMA","LU1066051498.USD","BK4139","BK4588","BK4583","BK4081","LU2468319806.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","LU1674673428.USD","LU1585245621.USD","BK4585","BK4215","IE00BKVL7J92.USD","MAA","IE00BZ1G4Q59.USD","BK4578","BK4568","LU1430594728.SGD","LU0234570918.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2544549439","title":"海普瑞(002399.SZ):依诺肝素钠注射液获得EMA新增生产商批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2544549439","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544549439?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:51","pubTimestamp":1750150299,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海普瑞(002399.SZ)发布公告,公司近日收到欧洲药品管理局(“EMA”)签发的关于依诺肝素钠注射液新增成品制造商的批准通知。本次公司坪山园区预灌封制剂生产线获得EMA的许可,标志着公司坪山园区生产的依诺肝素钠注射液已获得在欧洲经济区(EEA)实现商业化的资格,本次获批将为公司进一步推进制剂国际化战略提供更加充足的产能保障,切实提高公司市场竞争力;同时,依托强大的预灌针生产能力,以及公司成熟的自营销售网络及渠道,公司助力中国药企药品出海欧美市场的战略将得到有力的支持和推动,对公司未来业务拓展有深远且积极的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK4081","EMA","002399","09989","BK1191","BK0239","BK0188"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":0.0309},{"period":"3month","weight":0.0404},{"period":"ytd","weight":0.0404}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0321},{"period":"3month","weight":0.0922},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.1897},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Incorporated是一家北美能源服务提供商,成立于1998年7月23日,拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州,另外还在加拿大大西洋省、新墨西哥州和加勒比地区开展业务。Emera总部位于新斯科舍省哈利法克斯。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}